newsfilter
← Latest News
GlobeNewswire·

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory